Dolutegravir/rilpivirine

Global HIV Treatment Market Analysis Report 2023: A $25+ Billion Market by 2030 - Focus on Combination Therapies Gaining Momentum - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 29, 2023
AIDS, Pharmaceutical, Health, Hetero Drugs, Telehealth, Gilead Sciences, Drug development, EU, The, Prevalence, HIV, Islatravir, Sun Pharma, MPP, Public, Sustainable Development Goal 3, COVID-19, Collaboration, Health equity, Quality of life, Hope, ART, Research, ViiV Healthcare, Cipla, Medicines Patent Pool, Drug resistance, Non-governmental organization, Patient, Risk, Mylan, Hook effect, Aurobindo Pharma, Sustainable Development Goals, Artificial intelligence, Growth, Merck, FDA, UNAIDS, Pharmaceutical industry, Vaccine, Medical device, Bictegravir/emtricitabine/tenofovir alafenamide, Tenofovir alafenamide, Capsid, Dolutegravir/lamivudine, Lenacapavir, Dolutegravir/rilpivirine, Generic

The "Global HIV Treatment Market: Analysis By Product, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global HIV Treatment Market: Analysis By Product, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global HIV treatment market in 2022 stood at US$22.38 billion, and is likely to reach US$25.49 billion by 2030.
  • The global HIV treatment market is projected to grow at a CAGR of 1.42% during the forecast period of 2023-2030.
  • These ongoing efforts are instrumental in shaping the future of the global HIV treatment market.

CAN Community Health Welcomes Marlon Pittman to its Board of Directors

Retrieved on: 
Monday, January 10, 2022
Business development, Patient, Ryan White CARE Act, Board of directors, Case management, Ryan White, Pharmacy, STD, Mental health, Health, Health care, HIV/AIDS, HIV, Community health, Therapy, Program, Hepatitis C, Education, Quality of life, ViiV Healthcare, Business, Board, GlaxoSmithKline, Management, Pharmaceutical industry, Dolutegravir/rilpivirine

SARASOTA, Fla., Jan. 10, 2022 /PRNewswire-PRWeb/ -- CAN Community Health announces the appointment of veteran pharmaceutical industry executive Marlon Pittman to its Board of Directors.

Key Points: 
  • SARASOTA, Fla., Jan. 10, 2022 /PRNewswire-PRWeb/ -- CAN Community Health announces the appointment of veteran pharmaceutical industry executive Marlon Pittman to its Board of Directors.
  • In 2019 Mr. Pittman served as Business Development Director for CAN Community Health, assisting with the nonprofit's expansion into the Southern and Western United States.
  • CAN Community Health (CAN) is a not-for-profit, community-based organization with clinics in Florida, Arizona, New Jersey, South Carolina, Texas, and Virginia.
  • CAN provides medical, pharmacy, dental, case management, mental health, and comprehensive prevention and services such as nPEP, PrEP, and education.